Sandoz, >98% (HPLC), powder

Sandoz, >98% (HPLC), powder

Application

Sandoz 58-035 was used to induce simultaneous activation of unfolded protein response (UPR) and pattern recognition receptors (PRRs) in mouse peritoneal macrophages.3

Biochem/physiol Actions

Sandoz 58-035 inhibits the accumulation of cholesteryl esters and inhibits the esterification of cholesterol by 95% in arterial smooth muscle cells in culture.1 It does not affect the triglyceride metabolism by the gut.2

Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573935 Sandoz, >98% (HPLC), powder white 100 NBYATBIMYLFITE-UHFFFAOYSA-N 1S/C30H47NOSi/c1-5-6-7-8-9-10-11-15-23-33(3,4)24-22-30(32)31-29(28-16-13-12-14-17-28)25-27-20-18-26(2)19-21-27/h12-14,16-21,29H,5-11,15,22-25H2,1-4H3,(H,31,32) SIGMA-ALDRICH powder >98% (HPLC)
£945.75 (exc VAT) per 25MG
-
+
3573936 Sandoz, >98% (HPLC), powder white 100 NBYATBIMYLFITE-UHFFFAOYSA-N 1S/C30H47NOSi/c1-5-6-7-8-9-10-11-15-23-33(3,4)24-22-30(32)31-29(28-16-13-12-14-17-28)25-27-20-18-26(2)19-21-27/h12-14,16-21,29H,5-11,15,22-25H2,1-4H3,(H,31,32) SIGMA-ALDRICH powder >98% (HPLC)
£238.18 (exc VAT) per 5MG
-
+